Released Nov 10, 2026, after the close
10-Q filed Nov 10, 2026, 41 days after period end · 0001104659-26-125192
Atara reported a net loss of $2.2 million, or ($0.15) basic and diluted loss per share, for the third quarter 2026, as compared to net loss of $4.3 million, or ($0.32) basic and diluted loss per share, for the same period in 2025.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $1.22M | $3.45M | $40.19M | $2.14M |
| Net Income | -$2.23M | -$4.30M | -$21.91M |
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR
| -$69.80M |
| EPS Diluted | -$0.15 | -$0.32 | -$2.93 | -$16.40 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atara reported a third quarter 2026 net loss of $2.2 million, or ($0.15) per share, compared with $4.3 million, or ($0.32) per share, a year earlier.¶1
Total revenues were $1.2 million for the third quarter 2026, down $2.3 million from $3.5 million, primarily due to a one-time sale of clinical inventory in the prior year.¶2
Cash, cash equivalents and short-term investments totaled $9.9 million as of September 30, 2026, and net cash used in operating activities was $0.9 million for the quarter.¶3¶4
The FDA accepted the tab-cel BLA resubmission with a Class 2 PDUFA target action date of March 31, 2027, and approval would unlock a $31 million milestone payment from Pierre Fabre Laboratories.¶5¶6¶7
Atara expects its cash, cash equivalents and short-term investments, combined with operating efficiencies, will be sufficient to fund planned operations into mid-2027.¶8